These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14593612)

  • 1. [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].
    Duran-Sandoval D; Thomas AC; Bailleul B; Fruchart JC; Staels B
    Med Sci (Paris); 2003; 19(8-9):819-25. PubMed ID: 14593612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists.
    Gervois P; Fruchart JC; Staels B
    Int J Clin Pract Suppl; 2004 Oct; (143):22-9. PubMed ID: 16035393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical interest of PPARs ligands.
    Vergès B
    Diabetes Metab; 2004 Feb; 30(1):7-12. PubMed ID: 15029092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity.
    Guerre-Millo M; Gervois P; Raspé E; Madsen L; Poulain P; Derudas B; Herbert JM; Winegar DA; Willson TM; Fruchart JC; Berge RK; Staels B
    J Biol Chem; 2000 Jun; 275(22):16638-42. PubMed ID: 10828060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome.
    Pershadsingh HA
    Treat Endocrinol; 2006; 5(2):89-99. PubMed ID: 16542049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?
    Larsen TM; Toubro S; Astrup A
    Int J Obes Relat Metab Disord; 2003 Feb; 27(2):147-61. PubMed ID: 12586994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
    Zierath JR; Ryder JW; Doebber T; Woods J; Wu M; Ventre J; Li Z; McCrary C; Berger J; Zhang B; Moller DE
    Endocrinology; 1998 Dec; 139(12):5034-41. PubMed ID: 9832442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety issues and prospects for future generations of PPAR modulators.
    Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis.
    Guo Q; Sahoo SP; Wang PR; Milot DP; Ippolito MC; Wu MS; Baffic J; Biswas C; Hernandez M; Lam MH; Sharma N; Han W; Kelly LJ; MacNaul KL; Zhou G; Desai R; Heck JV; Doebber TW; Berger JP; Moller DE; Sparrow CP; Chao YS; Wright SD
    Endocrinology; 2004 Apr; 145(4):1640-8. PubMed ID: 14701675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
    Staels B; Fruchart JC
    Diabetes; 2005 Aug; 54(8):2460-70. PubMed ID: 16046315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glitazones (thiazolidinedione)].
    Ducobu J; Sternon J
    Rev Med Brux; 2000 Oct; 21(5):441-6. PubMed ID: 11109896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
    Wang M; Tafuri S
    J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic significance of peroxisome proliferator-activated receptor modulators in diabetes.
    Ram VJ
    Drugs Today (Barc); 2003 Aug; 39(8):609-32. PubMed ID: 14566384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PPARs, metabolic syndrome and cardiac diseases].
    Carvajal K; Hernández-Esquivel Mde L; Moreno-Sánchez R
    Arch Cardiol Mex; 2007; 77 Suppl 4():S4-66-76. PubMed ID: 18938701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.